BIO
Price
$324.08
Change
-$13.77 (-4.08%)
Updated
Dec 18, 04:59 PM (EDT)
56 days until earnings call
BMXMF
Price
$103.09
Change
-$3.94 (-3.68%)
Updated
Dec 18 closing price
Ad is loading...

BIO vs BMXMF

Header iconBIO vs BMXMF Comparison
Open Charts BIO vs BMXMFBanner chart's image
Bio-Rad Laboratories
Price$324.08
Change-$13.77 (-4.08%)
Volume$200
CapitalizationN/A
Biomerieux 69 Marcy L'Etoile
Price$103.09
Change-$3.94 (-3.68%)
Volume$70
CapitalizationN/A
BIO vs BMXMF Comparison Chart
Loading...
BIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BMXMF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BIO vs. BMXMF commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIO is a Buy and BMXMF is a Hold.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (BIO: $323.94 vs. BMXMF: $103.09)
Brand notoriety: BIO and BMXMF are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: BIO: 89% vs. BMXMF: 22%
Market capitalization -- BIO: $9.79B vs. BMXMF: $12.68B
BIO [@Medical Specialties] is valued at $9.79B. BMXMF’s [@Medical Specialties] market capitalization is $12.68B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.04B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIO’s FA Score shows that 1 FA rating(s) are green whileBMXMF’s FA Score has 1 green FA rating(s).

  • BIO’s FA Score: 1 green, 4 red.
  • BMXMF’s FA Score: 1 green, 4 red.
According to our system of comparison, BMXMF is a better buy in the long-term than BIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIO’s TA Score shows that 5 TA indicator(s) are bullish while BMXMF’s TA Score has 4 bullish TA indicator(s).

  • BIO’s TA Score: 5 bullish, 4 bearish.
  • BMXMF’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, both BIO and BMXMF are a good buy in the short-term.

Price Growth

BIO (@Medical Specialties) experienced а -5.14% price change this week, while BMXMF (@Medical Specialties) price change was +0.09% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -4.45%. For the same industry, the average monthly price growth was +1.34%, and the average quarterly price growth was -1.01%.

Reported Earning Dates

BIO is expected to report earnings on Feb 13, 2025.

Industries' Descriptions

@Medical Specialties (-4.45% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BMXMF($12.7B) has a higher market cap than BIO($9.79B). BMXMF has higher P/E ratio than BIO: BMXMF (25.51) vs BIO (3.64). BIO YTD gains are higher at: 4.633 vs. BMXMF (-1.355). BMXMF has higher annual earnings (EBITDA): 862M vs. BIO (-654.76M). BIO has more cash in the bank: 1.61B vs. BMXMF (553M). BMXMF has less debt than BIO: BMXMF (505M) vs BIO (1.41B). BMXMF has higher revenues than BIO: BMXMF (3.59B) vs BIO (2.67B).
BIOBMXMFBIO / BMXMF
Capitalization9.79B12.7B77%
EBITDA-654.76M862M-76%
Gain YTD4.633-1.355-342%
P/E Ratio3.6425.5114%
Revenue2.67B3.59B74%
Total Cash1.61B553M291%
Total Debt1.41B505M278%
FUNDAMENTALS RATINGS
BIO vs BMXMF: Fundamental Ratings
BIO
BMXMF
OUTLOOK RATING
1..100
1927
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
17
Undervalued
PROFIT vs RISK RATING
1..100
10075
SMR RATING
1..100
9261
PRICE GROWTH RATING
1..100
2858
P/E GROWTH RATING
1..100
8869
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BMXMF's Valuation (17) in the null industry is somewhat better than the same rating for BIO (79) in the Medical Specialties industry. This means that BMXMF’s stock grew somewhat faster than BIO’s over the last 12 months.

BMXMF's Profit vs Risk Rating (75) in the null industry is in the same range as BIO (100) in the Medical Specialties industry. This means that BMXMF’s stock grew similarly to BIO’s over the last 12 months.

BMXMF's SMR Rating (61) in the null industry is in the same range as BIO (92) in the Medical Specialties industry. This means that BMXMF’s stock grew similarly to BIO’s over the last 12 months.

BIO's Price Growth Rating (28) in the Medical Specialties industry is in the same range as BMXMF (58) in the null industry. This means that BIO’s stock grew similarly to BMXMF’s over the last 12 months.

BMXMF's P/E Growth Rating (69) in the null industry is in the same range as BIO (88) in the Medical Specialties industry. This means that BMXMF’s stock grew similarly to BIO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIOBMXMF
RSI
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend 2 days ago
64%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
71%
Bearish Trend 2 days ago
60%
Momentum
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
62%
MACD
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
59%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
64%
Bullish Trend 2 days ago
56%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
66%
Bullish Trend 2 days ago
55%
Advances
ODDS (%)
Bullish Trend 10 days ago
69%
Bullish Trend 6 days ago
62%
Declines
ODDS (%)
Bearish Trend 6 days ago
64%
N/A
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
61%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
64%
View a ticker or compare two or three
Ad is loading...
BIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BMXMF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
MTUL31.66N/A
N/A
ETRACS 2x Lvrgd MSCI US Mntm Fctr TR ETN
IAU49.91-0.15
-0.30%
iShares Gold Trust
GDIV15.66-0.09
-0.57%
Harbor Dividend Growth Leaders ETF
REZ83.16-0.83
-0.99%
iShares Residential & Multisector RE ETF
ADPV36.98-0.55
-1.46%
Adaptiv™ Select ETF

BIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, BIO has been loosely correlated with TMO. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if BIO jumps, then TMO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIO
1D Price
Change %
BIO100%
-1.49%
TMO - BIO
59%
Loosely correlated
-0.27%
RVTY - BIO
57%
Loosely correlated
-0.36%
DHR - BIO
56%
Loosely correlated
-0.28%
RGEN - BIO
55%
Loosely correlated
-1.73%
A - BIO
51%
Loosely correlated
-0.88%
More

BMXMF and

Correlation & Price change

A.I.dvisor tells us that BMXMF and SOAGY have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BMXMF and SOAGY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BMXMF
1D Price
Change %
BMXMF100%
N/A
SOAGY - BMXMF
26%
Poorly correlated
-3.12%
FONR - BMXMF
24%
Poorly correlated
-2.86%
SRTOY - BMXMF
23%
Poorly correlated
N/A
SNN - BMXMF
22%
Poorly correlated
+0.47%
BIO - BMXMF
21%
Poorly correlated
-1.49%
More